JPRN-jRCTs061230013RecruitingPhase 2
A phase II study to examine the efficacy and safety of tranilast for trigeminal neuralgia
Ikutame Daisuke0 sites15 target enrollmentStarted: May 12, 2023Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Enrollment
- 15
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 50age old to <= 80age old (—)
- Sex
- All
Inclusion Criteria
- •Patients who visit Tokushima University Hospital's Department of Fixed Prosthodontics, Temporomandibular Disorder Clinic, Department of Dental Anesthesiology
- •Patients diagnosed with trigeminal neuralgia according to the International Classification of Orofacial Pain
- •Patients aged 50 to 80
Exclusion Criteria
- •Patients with secondary trigeminal neuralgia who find organic changes in the brain by CT or MRI, patients taking warfarin, patients planning to move, pregnant women (especially within about 3 months) or possibly pregnant, patients deemed inappropriate by the principal investigator
Investigators
Similar Trials
Recruiting
Phase 1
A phase 2 study of ianalumab (VAY736) in patients with primary immune thrombocytopenia (ITP) previously treated with at least two lines of therapiesCTIS2022-503041-21-00ovartis Pharma AG40
Recruiting
Not Applicable
A phase 2 study to evaluate the efficacy and safety of temozolomide in advanced gastrointestinal stromal tumor patients with SDH deficiencyKCT0008244Asan Medical Center29
Unknown
Phase 2
A phase 2 study of K-134 in patients with intermittent claudicatioPeripheral arterial diseaseJPRN-jRCT2080221661Kowa Co., Ltd.330
Active, not recruiting
Not Applicable
A phase II study evaluating the efficacy and safety of lapatinib + vinorelbine in ErbB2 positive metastatic breast cancer patients after progression of chemotherapy or hormonal treatment in combination with lapatinib for metastatic diseasemetastatic breast cancerEUCTR2009-016826-15-ATCECOG30
Active, not recruiting
Phase 1
A phase II study evaluating the efficacy and safety of lapatinib + vinorelbine in ErbB2 positive metastatic breast cancer patients pretreated with chemotherapy or hormonal treatment in combination with lapatinib for metastatic diseasemetastatic breast cancerEUCTR2009-016826-15-CZCECOG30